Trial reportJournal of traditional Chinese medicine = Chung i tsa chih ying wen pan2026
Efficacy and safety of Dingluo nasal drops for the acute treatment of migraine: a pilot randomized trial.
Trial report in Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveTo evaluate the efficacy and safety of two doses of Dingluo nasal drops compared to placebo in the acute treatment of migraine.
methodsThis randomized, parallel-treatment, placebo-controlled, double-blind trial was conducted at Dongzhimen hospital, Beijing University of Chinese Medicine. Eligible participants were randomly assigned (1∶1∶1) to receive either full-dose Dingluo nasal drops, half-dose Dingluo nasal drops, or a placebo for three migraine attacks. The primary endpoint was the proportion of participants achieving pain freedom at 2 h postdose, assessed in all randomly assigned participants who received study medication.
resultsA total of 91 participants with 257 attacks were included in the statistical analysis. At 2 h postdose, Dingluo nasal drops were superior to placebo for freedom from pain [high dose
conclusionsDingluo nasal drops demonstrated superior efficacy to placebo in achieving pain freedom for acute migraine treatment. Mild nasal reactions were observed, with a trend toward reduced discomfort at the half-dose concentration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.